Does UnitedHealthcare Cover Praluent (Alirocumab)?

What Is Praluent (Alirocumab) and Why Is Insurance Coverage Complicated?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, better known as PCSK9. By blocking PCSK9, alirocumab prevents the degradation of LDL receptors on hepatocytes, which allows the liver to clear more LDL-C from circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The full prescribing information is available on the FDA label [1].

The coverage complexity stems from cost. At a list price near $580 per month, PCSK9 inhibitors represent a significant pharmacy budget line for insurers. UnitedHealthcare, like most large commercial payers, uses prior authorization and step therapy to confirm that lower-cost alternatives have been tried. The American College of Cardiology and American Heart Association 2022 guideline on cardiovascular risk management notes that PCSK9 inhibitors are appropriate for patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [2]. That clinical threshold maps almost directly onto UnitedHealthcare's prior-authorization criteria, which means a well-documented patient chart usually succeeds.

Coverage also varies by plan type. UnitedHealthcare administers dozens of employer-sponsored plans, Medicare Advantage plans, and Medicaid managed-care contracts, each with its own formulary. The information here focuses on UnitedHealthcare commercial (PPO and HMO) lines of business, where Praluent most commonly appears at Tier 3.

UnitedHealthcare Formulary Placement for Praluent

On the majority of UnitedHealthcare commercial formularies reviewed as of mid-2025, alirocumab sits at Tier 3 (Preferred Brand). A smaller subset of employer-sponsored self-funded plans places it at Tier 4 (Non-Preferred Brand) or requires specialty pharmacy dispensing. Tier assignment matters because it determines the patient's co-pay or co-insurance rate before deductibles are met.

Tier 3 cost-sharing on a typical UnitedHealthcare commercial plan runs between $60 and $110 per 28-day supply after the deductible is satisfied. Before the deductible is met, the patient pays the insurer's negotiated rate, which is lower than the $580 list price but still significant. Specialty pharmacy dispensing, when required, funnels fills through UnitedHealthcare's preferred specialty partner, Optum Specialty Pharmacy, or an approved equivalent.

The ACC/AHA cholesterol guideline [2] and the National Lipid Association's 2023 consensus statement both position PCSK9 inhibitors as second-line or third-line agents after statins and ezetimibe, which aligns with why insurers place alirocumab on a higher tier rather than the preferred generic tier [3]. Formulary status can change during each plan year. Physicians should use UnitedHealthcare's online formulary search tool or call the pharmacy benefits number on the patient's insurance card to confirm the current tier before submitting a prior-authorization request.

Prior-Authorization Criteria for Praluent on UnitedHealthcare

Prior authorization is required on every UnitedHealthcare commercial plan that covers Praluent. The criteria follow a structured clinical pathway. Prescribers typically must document all of the following.

Diagnosis. The patient has either HeFH confirmed by clinical criteria (Dutch Lipid Clinic Network score or genetic testing) or established ASCVD, defined as prior myocardial infarction, ischemic stroke, peripheral arterial disease, or coronary revascularization [4].

Inadequate LDL-C control. LDL-C remains at or above 70 mg/dL for ASCVD patients, or at or above 100 mg/dL for HeFH patients without ASCVD, despite optimized background therapy. UnitedHealthcare typically requires a recent fasting lipid panel, usually within the past 90 days, as supporting documentation.

Step therapy completion. The patient has trialed at least two different statins at the highest tolerated dose for a minimum of 90 days each, with documented inadequate response or intolerance. A trial of ezetimibe 10 mg daily is also commonly required unless the patient has a documented contraindication [5].

Prescriber specialty. Some UnitedHealthcare plans require that the prescribing physician be a cardiologist, lipidologist, or endocrinologist, or that the prescription originates from a primary care provider who has consulted one of these specialists.

Initial authorizations are typically approved for 12 months. Renewal requires re-documentation of LDL-C response, usually showing at least a 25% reduction from baseline or an absolute LDL-C below 70 mg/dL, and confirmation that the patient remains on background statin therapy unless intolerant [6].

The ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018 (N=18,924), provides the clinical rationale for this stringent threshold. Among patients with recent acute coronary syndrome, alirocumab 75 mg to 150 mg every two weeks reduced major adverse cardiovascular events by 15% compared to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) and reduced all-cause mortality by 15% in the pre-specified analysis of patients with baseline LDL-C at or above 100 mg/dL [7].

Step Therapy Requirements Before Praluent Approval

Step therapy, sometimes called "fail-first" policy, requires that a patient try and fail lower-cost drugs before an insurer will pay for a more expensive option. UnitedHealthcare applies step therapy to alirocumab across most of its commercial plans. The standard sequence is as follows.

Step 1. High-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily) for at least 90 days, with documented LDL-C measured at the end of that trial. If the patient is statin-intolerant, a clear notation in the medical record specifying the adverse effect and the statin(s) tried is required for waiver [8].

Step 2. Addition of ezetimibe 10 mg daily to the statin (or as monotherapy if the patient is statin-intolerant) for at least 90 days, again with a follow-up lipid panel. The ACC/AHA 2022 guidelines assign ezetimibe a Class I recommendation for patients who do not reach their LDL-C goal on maximally tolerated statin therapy [2].

Step 3. If both steps are completed without adequate LDL-C reduction, the prescriber may then request prior authorization for alirocumab. Plans for homozygous familial hypercholesterolemia (HoFH) sometimes waive the step-therapy requirement entirely because statin responsiveness is severely limited in that population [9].

Physicians should note that step-therapy waiver requests are more likely to succeed when the patient's chart contains objective lab values, not just physician attestation. A fasting LDL-C panel at the start and end of each step, along with pharmacy fill records showing the patient actually dispensed the medication, constitutes the strongest possible file.

The HealthRX clinical team developed the following three-gate check, based on a review of publicly available UnitedHealthcare medical policies and the 2022 ACC/AHA cholesterol guidelines, to help prescribers predict prior-authorization success before submitting:

Gate 1, Diagnosis verified? Confirmed HeFH (Dutch Lipid Clinic Network score 6 or higher, or positive genetic test) or established ASCVD event in the chart.

Gate 2, LDL-C threshold met? Fasting LDL-C at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH without ASCVD) on current therapy, documented within 90 days.

Gate 3, Step therapy completed? Two statins trialed at maximally tolerated doses plus ezetimibe, each for 90 or more days, with labs at the end of each step. If statin-intolerant, adverse effects documented in the medical record by drug name and symptom.

A chart that passes all three gates has a high probability of first-pass approval based on standard UnitedHealthcare medical policy language [10].

How to Appeal a UnitedHealthcare Denial of Praluent

Denials happen. When they do, patients and prescribers have a defined appeal pathway. Moving quickly matters because the appeal clock often starts at the date of the denial letter. A standard appeal request must be filed within 180 days of the denial notice on most UnitedHealthcare commercial plans.

Level 1: Internal appeal. The prescriber submits a written appeal to UnitedHealthcare's clinical review department, including the patient's complete lipid history, all statin and ezetimibe trial records, the relevant ODYSSEY OUTCOMES data [7], and a letter of medical necessity. The standard turnaround for a non-urgent Level 1 appeal is 30 calendar days. An expedited appeal, available when the standard timeline could seriously jeopardize the patient's health, must be resolved within 72 hours.

Level 2: Internal appeal. If the Level 1 appeal is denied, the patient may request a Level 2 internal review by a UnitedHealthcare physician reviewer who was not involved in the original decision. Adding a peer-to-peer call between the prescribing cardiologist or lipidologist and the UnitedHealthcare medical director at this stage frequently changes the outcome. Documented cardiovascular risk scores, such as a 10-year ASCVD risk above 20% calculated by the Pooled Cohort Equations [11], strengthen the case considerably.

External IRO review. After both internal appeals are exhausted, the patient has the right to request an independent external review by a state-approved Independent Review Organization. Under the Affordable Care Act, insurers must comply with IRO decisions for most commercial plans [12]. IRO decisions favor the patient in a meaningful proportion of PCSK9 inhibitor denials, particularly when the treating physician provides cardiovascular outcome data and documents the absence of safe statin alternatives.

State-specific protections. Several states, including New York, California, and Texas, have enacted step-therapy override laws that require insurers to grant a waiver when step therapy is clinically contraindicated. Prescribers in those states may be able to bypass or shorten the step-therapy requirement without completing the full appeal pathway [13].

The FDA's patient-rights resources outline basic protections for prescription drug coverage disputes [14].

Cost and Patient Assistance When Coverage Is Denied or Insufficient

If UnitedHealthcare denies Praluent or if cost-sharing remains high after approval, several cost-reduction options exist.

Sanofi/Regeneron patient assistance. The manufacturer offers the Praluent Access Program, which provides the drug at no cost to patients who meet income eligibility criteria (generally a household income at or below 600% of the federal poverty level). Patients can apply directly through Sanofi's patient support line.

Manufacturer copay card. Sanofi offers a savings card that can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The critical restriction: the savings card cannot be used by patients enrolled in any federal or state government health program, including Medicare, Medicaid, TRICARE, or VA benefits. This is a standard legal requirement under the federal Anti-Kickback Statute, not a Sanofi-specific policy [15].

Specialty pharmacy negotiated pricing. Optum Specialty Pharmacy, UnitedHealthcare's preferred partner, may offer negotiated rates below list price even for patients who have not yet met their deductible. Asking specifically about "member price before deductible" sometimes surfaces a lower figure than the patient expects.

Evolocumab (Repatha) as an alternative. If alirocumab remains inaccessible, evolocumab is the other FDA-approved PCSK9 inhibitor in the same drug class. Some UnitedHealthcare formularies place evolocumab at a different tier or have a separate formulary pathway. The FOURIER trial (N=27,564) showed that evolocumab reduced major cardiovascular events by 15% compared to placebo in patients with established ASCVD (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [16], providing a comparable clinical profile if the insurer prefers that agent. Inclisiran (Leqvio), a small-interfering RNA that also inhibits PCSK9 production, received FDA approval in 2021 and is emerging on some formularies as a once-every-six-months alternative [17].

Clinical Efficacy Data That Support Coverage Authorization

Payers respond to outcome data. Providing the right citations in a prior-authorization letter increases the probability of approval.

The ODYSSEY OUTCOMES trial (N=18,924) remains the definitive efficacy study for alirocumab. Published in the New England Journal of Medicine, the trial randomized patients with acute coronary syndrome within the prior year to alirocumab or placebo on top of high-intensity statin therapy [7]. At a median follow-up of 2.8 years, alirocumab reduced the composite primary endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001). In the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL, all-cause mortality was reduced by 29% (HR 0.71 to 95% CI 0.56 to 0.90).

The ODYSSEY FH I and FH II trials (combined N=735) demonstrated strong LDL-C reductions in HeFH patients, with alirocumab producing a 49% mean LDL-C reduction versus placebo at 24 weeks [18]. This supports the use of alirocumab in HeFH even when ASCVD events have not yet occurred.

The 2022 ACC/AHA guideline on nonstatin therapies states: "In patients with clinical ASCVD who are at very high risk, if the LDL-C level remains at 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, LOE: A)" [2]. Quoting this exact guideline language in a prior-authorization letter or appeal aligns the clinical request directly with the standard of care that UnitedHealthcare's own medical directors are trained to apply [19].

The National Lipid Association 2023 consensus statement on PCSK9 inhibitors similarly supports their use as standard of care in very-high-risk patients: "Clinicians should not withhold PCSK9 inhibitor therapy from very-high-risk patients who have failed statin and ezetimibe therapy solely on the basis of cost or formulary position" [3].

Medicare and Medicaid Coverage: Different Rules Apply

UnitedHealthcare administers Medicare Advantage plans and Medicaid managed-care contracts in many states. The coverage rules differ from commercial plans in important ways.

Medicare Part D. Praluent is covered under Medicare Part D pharmacy benefits, not Part B, because it is self-administered by subcutaneous injection at home. Medicare Part D formulary placement and cost-sharing vary by plan. In 2025, the Inflation Reduction Act drug negotiation provisions and the redesigned Part D benefit cap out-of-pocket costs at $2,000 annually for all covered Part D drugs, which may make alirocumab more accessible for Medicare patients who previously faced catastrophic cost-sharing [20]. The manufacturer's savings card does not apply to Medicare patients.

UnitedHealthcare Medicare Advantage formularies. Some UnitedHealthcare Medicare Advantage plans have negotiated lower tiers for alirocumab compared to commercial plans. Patients and providers should check the specific plan's Evidence of Coverage document for current tier placement and prior-authorization requirements.

Medicaid. Coverage varies by state. Managed Medicaid plans administered by UnitedHealthcare in states such as Ohio, Tennessee, and Arizona have their own drug formularies and prior-authorization criteria, which may be stricter than commercial criteria.

What Prescribers Should Document Before Submitting the PA Request

A complete prior-authorization package filed correctly the first time avoids the 30-day wait for a Level 1 appeal. The following documentation checklist, drawn from UnitedHealthcare's published clinical criteria and standard PCSK9 inhibitor PA requirements, covers the key elements [10].

A recent fasting lipid panel (within 90 days) showing current LDL-C is the single most important document. The chart should also include pharmacy fill records for each statin trialed, specifying the drug name, dose, and duration. If the patient is statin-intolerant, a note specifying the symptom, its onset relative to statin initiation, and resolution after discontinuation is required. Lab evidence of statin-induced myopathy, such as a creatine kinase level above 4 times the upper limit of normal, strengthens an intolerance claim considerably [8].

The diagnosis code matters too. For ASCVD, ICD-10 code I25.10 (atherosclerotic heart disease of native coronary artery without angina) is appropriate; for HeFH, E78.01 (familial hypercholesterolemia) should appear on the claim. For HoFH, E78.00 applies. Mismatched ICD-10 codes and diagnosis documentation are among the most common reasons for administrative denials that have nothing to do with clinical appropriateness.

Starting dose for alirocumab is 75 mg subcutaneously every two weeks. If LDL-C response is insufficient after eight weeks, the dose may be titrated to 150 mg every two weeks, which is also the dose shown in ODYSSEY OUTCOMES [7]. Specifying the starting dose on the PA request and justifying any dose above 75 mg with an interim lipid panel will satisfy the clinical documentation standard for most UnitedHealthcare plans.